Possible migraine drug delay weighs on Teva; Pharma to pay more under 2-year budget deal; Prescribed Reading: Earnings point to restructuring, not M&A; SeaGen, Pieris ink deal for bispecific I/O drugs
After Phase 2 trials of the drug failed to show a cognitive benefit in Alzheimer's, Boehringer will refocus its work on PDE9 inhibition around schizophrenia.
Staving off an extended government shutdown, the pact includes higher payments from drugmakers for Medicare recipients and more funds to fight the opioid crisis.
For $30 million upfront and $1.2 billion in potential milestones, SeaGen gains the rights to advance three candidates created through the collaboration.
The biotech says it will invest more in the U.S., although the $3.5 billion in total capital expenditures planned over the next five years is in line with past spending.
BROUGHT TO YOU BY – Syneos Health Commercial Trends for Biopharma in 2018
As consolidation blurs boundaries between IDNs, health insurers and retail pharmacies, leaders will plunge into healthcare AI, seek out new influencers, bet on value-based contracts, and purchase more services from contract commercial organizations (CCOs). For more on these trends, click here.
Our mission is to provide busy execs like you with an overview of the BioPharma industry in 60 seconds. BioPharma Dive is a product of Industry Dive. View other Industry Dive publications.
This email is optimized for display on mobile phones. BioPharma Dive is a product of Industry Dive, Inc.. 1575 Eye St NW, 4th Floor, Washington, DC 20005. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to [email protected]. You can unsubscribe or change which newsletters you receive anytime. See our full privacy policy.